Study guide
4.2 Leukocyte-Reduced, Washed, Frozen & Rejuvenated RBCs
Specialist in Blood Banking, SBB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes & Credential Maintenance 1.3 Study Strategy for SBB
2 Donors & Collection
2.1 Donor Qualification 2.2 Collection Methods & Adverse Reactions 2.3 Special Donations
3 Processing, Storage & Component QC
3.1 Processing, Testing & Labeling 3.2 Storage, Transport & Expiration 3.3 Blood Component Quality Control
4 Red Cell & Modified Components
4.1 Whole Blood & Red Blood Cells 4.2 Leukocyte-Reduced, Washed, Frozen & Rejuvenated RBCs 4.3 Irradiated Components 4.4 Granulocytes
5 Platelets, Plasma & Cellular Products
5.1 Platelets 5.2 Plasma & Cryoprecipitated AHF 5.3 Apheresis Products & Fractionation Products 5.4 Hematopoietic Progenitors
6 Genetics, ABO & Rh
6.1 Blood Group Genetics & Molecular Inheritance 6.2 ABO & Lewis Systems 6.3 Rh System 6.4 MNS, P1PK/Globoside & Ii
7 Other Blood Groups & Role in Transfusion
7.1 Kell, Kidd, Duffy & Lutheran 7.2 Other Systems & High/Low-Prevalence Antigens 7.3 HLA, Platelet-Specific & Granulocyte Antigens 7.4 Immunogenicity & Antigen Prevalence
8 Immunology Foundations
8.1 Immune Response 8.2 Immunoglobulins 8.3 Antigen-Antibody Interactions 8.4 Complement
9 Physiology, Hemostasis & HDFN
9.1 Physiology of Blood 9.2 Hemostasis and Coagulation 9.3 HDFN Pathophysiology & Detection 9.4 HDFN Treatment & Prevention
10 Cytopenias & Transplantation
10.1 Immune & Nonimmune Anemia 10.2 Thrombocytopenia & Neutropenia 10.3 Solid Organ Transplantation Support 10.4 Hematopoietic Progenitor Cell Transplantation
11 Routine Serologic Testing
11.1 Blood Grouping Tests 11.2 Antibody Detection & Crossmatch 11.3 Antibody Identification & Clinical Significance 11.4 Direct Antiglobulin Testing & Reagents
12 Special Serologic Methods
12.1 Enzymes, Enhancement Media & Lectins 12.2 Adsorptions, Elutions & Titrations 12.3 Cell Separations, Neutralization & Thiol Reagents 12.4 Chloroquine Diphosphate & EDTA-Glycine Acid
13 Molecular Platforms & Serologic QA
13.1 Molecular Blood Group Techniques 13.2 ELISA, Immunofluorescence, Solid Phase & Column Agglutination 13.3 Serologic Quality Assurance
14 Indications, Component Therapy & PBM
14.1 Indications for Transfusion 14.2 Component Therapy 14.3 Blood Administration & Patient Blood Management
15 Adverse Effects of Transfusion
15.1 Immunologic Transfusion Reactions 15.2 Nonimmunologic Reactions 15.3 Transfusion-Transmitted Diseases
16 Apheresis & Extracorporeal Circulation
16.1 Therapeutic Apheresis 16.2 Extracorporeal Circulation
17 Quality, Safety, Math & Instrumentation
17.1 Quality Assessment & Troubleshooting 17.2 Laboratory Safety 17.3 Laboratory Mathematics 17.4 Instrumentation
18 Laboratory Administration (SBB Only)
18.1 Financial Management 18.2 Operations & Information Technology 18.3 Personnel, Education & Training 18.4 Quality Management, Risk & Tissue Management
4.2 Leukocyte-Reduced, Washed, Frozen & Rejuvenated RBCs
Key Takeaways Explain This Topic AI
AABB standards require fewer than 5 x 10^6 residual leukocytes in a leukocyte-reduced RBC unit; pre-storage filtration also prevents cytokine accumulation and reduces febrile nonhemolytic reactions, HLA alloimmunization, and CMV transmission risk, but does not reliably prevent TA-GVHD.
Washed RBCs are indicated for severe or recurrent allergic reactions and for IgA-deficient patients with documented anti-IgA antibodies and an anaphylaxis history when IgA-deficient units are unavailable; washing opens the system and shortens the outdate to 24 hours at 1-6°C.
Frozen (deglycerolized) RBCs use the high-glycerol method (approximately 40% w/v glycerol, storage at -65°C or colder) to preserve rare or autologous units for up to 10 years; deglycerolization must recover at least 80% of the original red cells.
Manual, open-system deglycerolization carries a 24-hour outdate at 1-6°C, while a validated, FDA-cleared closed-system automated washer extends the post-deglycerolization outdate to 14 days in an additive solution such as AS-3.
Rejuvenation solutions restore 2,3-DPG and ATP in RBC units nearing outdate; rejuvenated units must be washed before immediate transfusion (24-hour open-system outdate) or glycerolized and frozen for long-term storage.
Last updated: July 2026
Leukocyte-Reduced Red Blood Cells
Leukocyte reduction (LR) removes residual white blood cells from a red cell or platelet unit using a specialized filter, most often applied pre-storage (within 24-72 hours of collection, before significant leukocyte fragmentation and cytokine release) rather than post-storage (bedside or laboratory filtration just before transfusion). Pre-storage filtration is now the dominant U.S. practice because it also prevents the accumulation of leukocyte-derived cytokines (IL-1, IL-6, IL-8, TNF-alpha) that build up in the supernatant during storage and that post-storage filtration cannot remove.
AABB Standard: a leukocyte-reduced unit must retain fewer than 5 x 10^6 residual leukocytes per unit (for RBCs and whole blood-derived platelets) while retaining at least 85% of the original red cell content.
Leukoreduction addresses three distinct clinical problems, and the SBB must be able to separate them.
Problem Mechanism How LR Helps
Febrile nonhemolytic transfusion reaction (FNHTR) Recipient antibodies react with donor leukocyte antigens, or accumulated cytokines in stored plasma trigger fever Pre-storage LR removes leukocytes before cytokines accumulate, reducing FNHTR incidence
HLA alloimmunization / platelet refractoriness Donor leukocytes expose the recipient to foreign HLA class I/II antigens, provoking antibody formation Removing leukocytes reduces the antigen load driving alloimmunization
Transfusion-transmitted CMV CMV is latent within donor leukocytes (particularly monocytes), not free in plasma or carried by mature red cells/platelets Removing leukocytes below the LR threshold is considered by AABB to confer risk equivalent to a CMV-seronegative unit
Exam trap: leukoreduction does not prevent transfusion-associated graft-versus-host disease (TA-GVHD). Enough intact, functional T-lymphocytes can survive even below the 5 x 10^6 threshold to engraft in a severely immunocompromised or HLA-matched recipient. Only irradiation reliably prevents TA-GVHD, covered in the next section of this chapter.
Washed Red Blood Cells
Washing replaces a red cell unit's plasma with isotonic saline (with or without a small amount of dextrose), removing plasma proteins, antibodies, potassium, microparticles, and any residual additive solution or glycerol. Because washing opens the closed collection system, the unit becomes a contamination risk and must carry a shortened outdate of 24 hours at 1-6°C (or 4 hours at 20-24°C for platelets), regardless of how much time remained on the original unit.
Primary indications for washed RBCs:
Severe or recurrent allergic/anaphylactic transfusion reactions that persist despite premedication (antihistamines, antipyretics) and are not resolved by simply slowing the infusion.
IgA deficiency with documented anti-IgA antibodies and a history of anaphylaxis , when IgA-deficient donor units are not available. Washing is not indicated for asymptomatic IgA-deficient patients without a reaction history — the exam consistently tests this distinction, because washing every IgA-deficient patient's blood is neither necessary nor standard practice.
Neonatal exchange transfusion and intrauterine transfusion , where washing removes potassium and additive-solution constituents that could be harmful in the very small blood volumes of a fetus or neonate.
Hyperkalemia risk in patients requiring large-volume or rapid transfusion, since washing removes accumulated supernatant potassium.
Exam trap: washing is not a substitute for leukoreduction and does not reliably prevent TA-GVHD — a washed unit still contains substantial numbers of intact leukocytes unless it was separately leukoreduced or irradiated.
Frozen (Deglycerolized) Red Blood Cells
Frozen storage extends red cell shelf life from weeks to years by adding a cryoprotectant, most commonly glycerol , before freezing. The high-glycerol method (HGM) is the standard U.S. approach: RBCs are glycerolized to a final concentration of approximately 40% (w/v) , frozen slowly, and stored at -65°C or colder , permitting storage for up to 10 years . The less common low-glycerol method (LGM) uses about 20% (w/v) glycerol with rapid controlled-rate freezing and ultra-cold storage below -120°C, and is used mainly in specialized or military settings.
Primary uses: long-term storage of rare or autologous units (rare phenotypes, units for alloimmunized patients with multiple antibodies, and directed autologous donations) and strategic or military blood reserves.
Before transfusion, a frozen unit must be thawed and deglycerolized . Glycerol is markedly hypertonic; infusing a glycerolized red cell directly would draw water out of the cell and cause it to crenate, and allowing glycerol to re-enter isotonic plasma too quickly after transfusion would let water rush back into the cell and cause hemolysis. Deglycerolization removes the glycerol gradually through sequential washes of decreasing tonicity — typically hypertonic (12%) saline followed by isotonic (0.9%) saline with dextrose — using an automated cell washer. The final unit must recover at least 80% of the red cells present in the original unit.
Open vs. closed system and outdate — a key SBB distinction:
- Deglycerolization Method System Type Post-Thaw Outdate
- Manual, open bag/bowl washing Open 24 hours at 1-6°C
Automated, FDA-cleared closed-system processor with sterile docking Closed, validated 14 days at 1-6°C when resuspended in an additive solution such as AS-3
This mirrors the general storage principle that governs washed RBCs, irradiated components, and pooled products throughout blood banking: opening a sterile system to room air always shortens the outdate to protect against bacterial contamination, and only a validated, sterile closed-system device can preserve a longer post-processing shelf life.
Rejuvenated Red Blood Cells
Rejuvenation uses an FDA-approved rejuvenating solution incubated with red cells to restore or increase 2,3-DPG and ATP that were depleted during liquid storage. Rejuvenation can be applied to units nearing or at outdate — for example, CPD units at up to 24 days, CPDA-1 units at up to 38 days, or AS-1 units at up to 42 days of storage — bringing 2,3-DPG and ATP back to normal or supranormal levels.
Rejuvenation has two distinct downstream paths, and the SBB must know both.
Rejuvenate, then wash, then transfuse immediately — because rejuvenation solution itself must be removed before infusion, the rejuvenated unit becomes an open-system washed product with the same 24-hour, 1-6°C outdate described above.
Rejuvenate, then glycerolize and freeze — this is the more common strategic use: rejuvenating a unit just before it would otherwise expire rescues it for long-term frozen storage (up to 10 years) with restored oxygen-carrying function, rather than discarding it at outdate.
Exam trap: rejuvenation restores 2,3-DPG/ATP function; it does not extend the liquid (unfrozen) shelf life of a unit on its own, does not remove leukocytes, and does not replace irradiation for TA-GVHD prevention. It is a biochemical/metabolic intervention, not a sterility or immunologic one.